Consequently, chemotherapies using small molecule inhibitors of mutated BRAF, such as vemurafenib and dabrafenib, have generated positive clinical responses in approximately half of BRAF-mutated melanoma patients [5,6]. This evidence concerns the gene BRAF and melanoma.